CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer. Our innovative approach DETECTS, MARKS, and KILLS only cancer cells. By making cancer cells look like well immunized common diseases such as measles or chickenpox, we intend to use the body’s natural immune system to easily kill the cancer cells. We have also created our first cancer drug candidate – a single-disease specific immunotherapy targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults. We look forward to the day when treating cancer will be as simple as getting a shot – a better way to fight cancer.

Our Journey

• March - June 2021

  CancerVax was incorporated, raised $2 million seed funding and executed a Sponsored Research Agreement with UCLA targeting Ewing sarcoma.

• November 2021

  CancerVax filed a provisional patent describing technology that forms the basis of our Universal Cancer Treatment Platform.

• July 2022

  CancerVax executed a second Sponsored Research Agreement with UCLA to develop the Universal Cancer Treatment Platform.

• July 2024

  CancerVax filed a provisional patent application describing a novel messenger RNA (mRNA) approach to DETECT and MARK cancer cells with precision.

• August 2024

  CancerVax entered into a research agreement with Flashpoint Therapeutics to perform research on its newly patent-pending Universal Cancer Treatment platform.